| Name | Anpario |
|---|---|
| Epic | ANP |
| Isin | GB00B3NWT178 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 336.67p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £68.39 | Debt ratio | n/a |
| Shares in issue | 20.31 | Debt-to-equity ratio | n/a |
| P/E ratio | 16.8 | Assets / equity ratio | n/a |
| Total dividends per share | 10.70p | Price to book value | n/a |
| Dividend yield | 4.2 | ROCE | 10.9 |
| Dividend cover | 1.44 | EPS growth | -14 |
| Earning per share | 13.51 | 52-week high / low | 227.50p / 355.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-07-11 | 2024-07-26 | 7.50p |
| Interim | 2023-11-09 | 2023-11-24 | 3.20p |
| Final | 2023-07-13 | 2023-07-28 | 7.35p |
| Interim | 2022-11-10 | 2022-11-25 | 3.15p |
| Final | 2022-07-14 | 2022-07-29 | 7.00p |
| Interim | 2021-11-11 | 2021-11-26 | 3.00p |
| Final | 2021-07-15 | 2021-07-30 | 6.25p |
| Interim | 2020-11-12 | 2020-11-27 | 2.75p |
| Final | 2020-07-16 | 2020-07-31 | 5.50p |
| Company name | Anpario |
|---|---|
| Address | Manton Wood Enterprise Park, Worksop, Nottinghamshire, England, United Kingdom, S80 2RS |
| Telephone | +44 (0)1909 537380 |
| Website | http://www.anpario.com |
| Director | Position |
|---|---|
| Mr Richard Edwards | CEO |
| Mr Tim Pollock | Non-Executive Director |
| Ms Karen Prior | Executive Director |
| Mr Matthew Robinson | Non-Executive Chairman |
| Mr Marc Wilson | Group Finance Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 10.64 | 11.38 | 11.29 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 16.13 | 17.3 | 17.44 |
| Inventory / work in progress | 6.35 | 9.87 | 7.58 |
| Trade and other receivables | 6.82 | 7 | 6.87 |
| Cash and equivalents | 10.54 | 11.74 | 13.74 |
| Other current assets and asset held for resale | 0.36 | 2.62 | 0.55 |
| Total of all assets | 40.19 | 48.53 | 47.98 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 4.69 | 4.66 | 5.24 |
| Long term liabilities | 1.85 | 2.57 | 2.44 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 6.54 | 7.22 | 7.68 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 33.65 | 41.31 | 40.3 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 4.62 | 5.62 | 5.45 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 21.54 | 31.21 | 30.1 |
| Share premium account | 15.05 | 14.93 | 11.55 |
| Total equity | 33.65 | 41.31 | 40.3 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 2.52 | 3.56 | 5.65 |
| Pre-tax profit | 2.75 | 3.68 | 5.7 |